Clinical Trials Logo

Filter by:
NCT ID: NCT01326676 Withdrawn - Clinical trials for Cardiovascular Disease

Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial

PESCA
Start date: February 2011
Phase: Phase 3
Study type: Interventional

Medications that lower blood pressure and cholesterol are known to improve the shape and function of our blood vessels. These improvements include a reduction in the thickness of the wall of the carotid artery (the main artery that runs up the neck to supply the brain) and a reduction in the stiffness of arteries generally including the main central artery -the aorta. Such medications are in the polypill (the Red Heart Pill) that is being used in the UMPIRE Study. In UMPIRE, patients' reported adherence to taking the single, once daily polypill is being compared to adherence to medications taken as separate tablets (usual care).The aim of the PESCA sub-study is to see whether or not the polypill differs from 'usual care' in its direct effects on blood vessels as shown by ultrasound examination of the carotid arteries and assessment of central (aortic) blood pressure.

NCT ID: NCT01325792 Completed - Clinical trials for Ventral Incisional Hernia

Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement

COBRA
Start date: February 2011
Phase: N/A
Study type: Observational

Prospective, multicenter, observational study to evaluate performance of GORE® BIO-A® Tissue Reinforcement when used to reinforce midline fascial closure in single-staged open complex ventral incisional hernia repair.

NCT ID: NCT01325623 Completed - Epilepsy Clinical Trials

Seizure Detection and Automatic Magnet Mode Performance Study

E-36
Start date: March 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to confirm cardiac-based seizure detection in Cyberonics Model 106 VNS Therapy System.

NCT ID: NCT01324947 Completed - Multiple Myeloma Clinical Trials

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Start date: March 1, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of pomalidomide monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in study CC-4047-MM-003 (NCT01311687) and discontinued treatment with high-dose dexamethasone due to disease progression.

NCT ID: NCT01324479 Completed - Solid Tumors Clinical Trials

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Start date: February 29, 2012
Phase: Phase 1
Study type: Interventional

This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.

NCT ID: NCT01324037 Completed - Clinical trials for Suspected Upper Extremity Deep Vein Thrombosis

Diagnostic Algorithm in Suspected Upper Extremity Deep Vein Thrombosis

Armour
Start date: March 2010
Phase: N/A
Study type: Interventional

Deep vein thrombosis (DVT) of the arm, officially called upper extremity DVT is a rare disorder and accounts for up to 1-4% of all cases of deep vein thrombosis. In case of a thrombosis, there is a blood clot in one of the veins, which should be treated with blood thinners (anticoagulants). The aim of the present study is to see whether it is safe to use a combination of tests for the diagnosis of arm thrombosis. In all patients, we will use a clinical decision rule (clinical judgement) and a laboratory test (D-dimer testing), in most patients also an ultrasound of the arm will be done. The combination of these tests was found to be safe and effective in patients with thrombosis of the legs.

NCT ID: NCT01323452 Completed - Clinical trials for Entecavir for Chronic Hepatitis B Patients

Entecavir for Chronic Hepatitis B

Start date: November 2010
Phase: N/A
Study type: Observational

The primary aim of this study is to asses the efficacy (both virological and clinical) and safety of ETV in both NA-naïve and NA-experienced chronic hepatitis B patients, and to explore baseline factors associated with virologic reponse (VR) to ETV.

NCT ID: NCT01323244 Completed - Hepatitis C Clinical Trials

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Start date: December 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy of a treatment with TMC435 in combination with peginterferon alfa-2a and ribavirin in patients who did not clear their hepatitis C infection with peginterferon alfa-2a and ribavirin alone within a previous trial conducted by Tibotec, or who participated in Tibotec trials in which antivirals directed against hepatitis C virus (HCV) were evaluated for short periods of time.

NCT ID: NCT01323153 Completed - Clinical trials for Coronary Heart Disease

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Start date: March 2011
Phase: Phase 3
Study type: Interventional

This double-blind, randomized, placebo-controlled, multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome (ACS). Treatment will be initiated within 1 week after the ACS. Patients will be randomized to receive dalcetrapib 600 mg as daily oral doses or matching placebo. The anticipated time on study treatment is 20 weeks.

NCT ID: NCT01322490 Completed - Clinical trials for Prostate Cancer Metastatic

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Prospect
Start date: November 28, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.